Federated Hermes’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Buy
+1,386,591
New +$9.49M 0.02% 616
2024
Q2
Sell
-198
Closed -$1.06K 2079
2024
Q1
$1.06K Buy
198
+1
+0.5% +$5 ﹤0.01% 1959
2023
Q4
$989 Sell
197
-63
-24% -$198 ﹤0.01% 1974
2023
Q3
$439 Sell
260
-15,495
-98% -$31.1K ﹤0.01% 2046
2023
Q2
$43.8K Sell
15,755
-6,252
-28% -$17.7K ﹤0.01% 1694
2023
Q1
$40.1K Buy
+22,007
New +$68.4K ﹤0.01% 1755
2022
Q2
Sell
-1,998
Closed -$11K 2215
2022
Q1
$11K Buy
1,998
+3
+0.2% +$18 ﹤0.01% 1876
2021
Q4
$12K Sell
1,995
-2,529
-56% -$19K ﹤0.01% 1913
2021
Q3
$44K Sell
4,524
-34
-0.7% -$374 ﹤0.01% 1874
2021
Q2
$65K Buy
4,558
+4,466
+4,854% +$73.8K ﹤0.01% 1840
2021
Q1
$2K Buy
+92
New +$2.38K ﹤0.01% 2126
2020
Q3
Sell
-175
Closed -$2K 2299
2020
Q2
$2K Buy
+175
New +$988 ﹤0.01% 2082
2020
Q1
Sell
-898
Closed -$3K 2289
2019
Q4
$3K Hold
898
﹤0.01% 1999
2019
Q3
$1K Sell
898
-1,903
-68% -$2.36K ﹤0.01% 2106
2019
Q2
$3K Hold
2,801
﹤0.01% 2046
2019
Q1
$4K Hold
2,801
﹤0.01% 1998
2018
Q4
$3K Buy
2,801
+915
+49% +$2.09K ﹤0.01% 2045
2018
Q3
$7K Sell
1,886
-156
-8% -$493 ﹤0.01% 2003
2018
Q2
$6K Buy
2,042
+512
+33% +$1.9K ﹤0.01% 1991
2018
Q1
$6K Sell
1,530
-279
-15% -$1.22K ﹤0.01% 1950
2017
Q4
$8K Buy
1,809
+239
+15% +$1.13K ﹤0.01% 1919
2017
Q3
$9K Buy
1,570
+855
+120% +$5.27K ﹤0.01% 1860
2017
Q2
$5K Buy
+715
New +$3.09K ﹤0.01% 1947

Other funds holding IBRX

Federated Hermes's IBRX Position: Q1 2026 in Review

Federated Hermes opened a new position in ImmunityBio (IBRX) in Q1 2026: 1,386,591 shares worth $10.6M. The stake represents 0.02% of the portfolio and ranks #616 among its holdings. This is a return to the name: Federated Hermes previously reported a position in IBRX as recently as Q1 2024.

Federated Hermes first reported a position in IBRX in Q2 2017 and has held it in 23 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Federated Hermes held 1,386,591 shares of ImmunityBio worth $10.6M as of Q1 2026.
  • ImmunityBio was a new Federated Hermes position in Q1 2026.
  • ImmunityBio made up 0.02% of Federated Hermes's portfolio in Q1 2026, its #616 holding.
  • Federated Hermes first reported a position in ImmunityBio in Q2 2017 and has held it in 23 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.